Novartis has sponsored a new programme to improve ophthalmic care across the UK through needs-based medical education, training and support.
The Excellence in Ophthalmology programme, run by a steering committee of clinical experts, aims to highlight the challenges in delivering ophthalmic care and to identify and co-ordinate initiatives to help optimise patient outcomes.
Focusing initially on retinal disease, the programme will go on to explore other areas of ophthalmic care as needed.
Novartis Pharmaceuticals UK has provided financial support and project management advice for the programme.
Excellence in Ophthalmology was launched at its first congress, held in London on 3–4 February 2012.
The congress brought together 250 consultant ophthalmologists, ophthalmic nurses, optometrists, retinal screeners, AMD co-ordinators and Business Managers to receive an introduction to the programme and discuss such issues as the changing role of the allied healthcare professional and new models of service design.
Mark Collinson, Head of Ophthalmics at Novartis, said: “Novartis has a long-term commitment to ophthalmic care and improving the lives of individuals with retinal disease. Excellence in Ophthalmology is a demonstration of this commitment and we hope that this initiative, designed by leading experts in eye care, will enhance support to ophthalmology in the UK.”
A global pharmaceutical company based in Basel, Switzerland, Novartis offers a diversified portfolio that includes research-based medicines, eye care, generic drugs and vaccines.